Buprenorphine HCl and Naloxone HCl: cost and payments to doctors
What Medicare Part D paid pharmacies for Buprenorphine HCl and Naloxone HCl, and the payments that named it as the associated drug or biological under the Sunshine Act for program years 2019–2025.
Was your doctor paid by Mylan Pharmaceuticals Inc.?
Mylan Pharmaceuticals Inc. reported the most payments naming Buprenorphine HCl and Naloxone HCl. Search your clinician to see whether they are among them — and what else they were paid for.
Finding a payment is not a finding of wrongdoing — most reported payments are a meal during a presentation. What matters is the kind, the size, and how it compares with their peers, which is what the profile shows.
- Total reported
- $18K
- Providers
- 0
- Transactions
- 3
- Average per transaction
- $6,020
The per-transaction average — $6,020 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. No payment naming this product was reported to an individual clinician. The Sunshine Act also covers payments to teaching hospitals as institutions — research funding, grants and device loans — and for this product that is all of it.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Mylan Pharmaceuticals Inc. | $18,060 | 100.0% |
Other products from Mylan Pharmaceuticals Inc.
The company that reported the most payments naming Buprenorphine HCl and Naloxone HCl also reports against these.
- Xulane$298,032
- Dymista$28,192
- Yupelri$11,718
- Perforomist$11,512
- Olux$11,346
- Clindamycin Phosphate and Benzoyl Peroxide$11,125
- Olux-E$8,532
- Vusion$8,184
- Glatiramer Acetate$7,900
- Symfi Lo$2,701